EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF

Maxime Guenoun, Serge Cohen, Marc Villaceque iD, Ali Sharareh iD, Jerome Schwartz, Olivier Hoffman, Jean-Claude Dib iD, Leon Ouazana, Serge Assouline, Eric Parrens iD, Thierry Garban, Vincent Pradeau und 8 weitere

Europace · 2023

DOI: 10.1093/europace/euad302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Europace, 2023. Verfasst von Maxime Guenoun und 19 weiteren Autor:innen. Beteiligte Einrichtung: Almaviva Santé, Marseille, France. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Kidney Failure, Chronic. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Since the introduction of direct oral anticoagulant (DOAC) for atrial fibrillation (AF) therapy, inappropriate and/or underdosing of these drugs has been a major clinical challenge. We evaluated the characteristics of patients with AF treated with inappropriate and low-dose DOACs. Methods and results Patients with AF treated with inappropriate and low-dose DOACs from October 2021 to December 2021 were evaluated from the French National Prospective Registry (PAFF). We evaluated 1890 patients with AF receiving DOACs (apixaban 55%, dabigatran 7%, and rivaroxaban 38%). Inappropriate dosing was noted in 18% of the population. Patients with appropriate dosing had less comorbidities: younger age (75 ± 10 vs. 82 ± 8 years old, P < 0.0001), reduced chronic renal failure (26 vs. 61%, P < 0.0001), and lower CHA2DS2VASc and HASBLED scores (3 ± 2 vs. 4 ± 3, P < 0.0001; 2 ±1 vs. 2 ± 2, P < 0.0001), respectively. In multivariate analysis, older age (P < 0.0001) and a higher CHA2DS2VASc score (P = 0.0056) were independently associated with inappropriate DOAC dosing. Among 472 patients (27%) treated with low-dose rivaroxaban or apixaban, 46% were inappropriately underdosed. Patients inappropriately underdosed were younger (82.3 ± 8.4 vs. 85.9 ± 5.9 years, P < 0.0001) with less chronic renal disease (47 vs. 98%, P < 0.0001). However, these patients had higher rates of prior haemorrhagic events (18 vs. 10%, P = 0.01), clopidogrel use (11 vs. 3%, P = 0.0002), and apixaban prescription (74 vs. 50%, P < 0.0001).

Conclusion

Within this large registry, DOACs were associated with inappropriate dosing in 18% of cases. Independent predictors of inappropriate dosing were high CHA2DS2VASc scores and older age. Moreover, 46% of patients treated with low-dose DOACs were inappropriately underdosed and more frequently in patients treated with apixaban.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeKidney Failure, ChronicHumansAgedAged, 80 and overRivaroxabanAnticoagulantsRetrospective StudiesDabigatranRegistriesAdministration, Oral

Stichwörter der Autor:innen

Atrial fibrillationDirect oral anticoagulantInappropriate dosing

Substanzen

RivaroxabanAnticoagulantsDabigatran

Autor:innen und Institutionen

  • Almaviva Santé, Marseille, France.
  • College National des Cardiologues Français, Paris, France.
  • Syndicat National des Cardiologues, Paris, France.
  • Clinique Ambroise Paré, Neuilly sur Seine, France.
  • Clinique Tivoli-Ducos, Bordeaux, France.
  • Institut Arnaud Tzanck, Saint Laurent du Var, France.

ORCID-Profile: Marc Villaceque, Ali Sharareh, Jean-Claude Dib, Eric Parrens, Benoit Lequeux, Charlotte Cohen, Francois Dievart, Tarvinder S Dhanjal, Pierre Sabouret, Nicolas Lellouche

Förderung

  • Bayer

Zitieren

APA

Guenoun, M., Cohen, S., Villaceque, M., Sharareh, A., Schwartz, J., Hoffman, O., Dib, J. C., Ouazana, L., Assouline, S., Parrens, E., Garban, T., Pradeau, V., Guedj-Meynier, D., Lequeux, B., Cohen, C., Durand, P., Dievart, F., Dhanjal, T. S., Sabouret, P., & Lellouche, N. (2023). Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF. Europace. https://doi.org/10.1093/europace/euad302

Vancouver

Guenoun M, Cohen S, Villaceque M, Sharareh A, Schwartz J, Hoffman O, et al. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF. Europace. 2023. doi:10.1093/europace/euad302

BibTeX
@article{Guenoun2023,
  author = {Guenoun, Maxime and Cohen, Serge and Villaceque, Marc and Sharareh, Ali and Schwartz, Jerome and Hoffman, Olivier and Dib, Jean-Claude and Ouazana, Leon and Assouline, Serge and Parrens, Eric and Garban, Thierry and Pradeau, Vincent and Guedj-Meynier, Dominique and Lequeux, Benoit and Cohen, Charlotte and Durand, Philippe and Dievart, Francois and Dhanjal, Tarvinder S and Sabouret, Pierre and Lellouche, Nicolas},
  title = {Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad302}
}
Kostenlos starten →